Compare AUB & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUB | APGE |
|---|---|---|
| Founded | 1902 | 2022 |
| Country | United States | United States |
| Employees | 3064 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.7B |
| IPO Year | N/A | 2023 |
| Metric | AUB | APGE |
|---|---|---|
| Price | $34.70 | $79.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $42.19 | ★ $109.25 |
| AVG Volume (30 Days) | 921.5K | ★ 1.0M |
| Earning Date | 04-23-2026 | 03-02-2026 |
| Dividend Yield | ★ 4.17% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.24 | N/A |
| Revenue Next Year | $4.52 | N/A |
| P/E Ratio | $19.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.85 | $26.20 |
| 52 Week High | $42.18 | $85.04 |
| Indicator | AUB | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 39.38 | 60.14 |
| Support Level | $34.59 | $73.06 |
| Resistance Level | $36.99 | $81.04 |
| Average True Range (ATR) | 0.91 | 4.62 |
| MACD | 0.17 | 0.96 |
| Stochastic Oscillator | 45.24 | 73.26 |
Atlantic Union Bankshares Corp is a financial and bank holding company based in the U.S. Through its community bank subsidiary and non-bank financial services affiliates, the company provides financial services, including banking, trust, and wealth management. It offers consumers and businesses a wide range of banking and related financial services, including checking, savings, certificates of deposit, and other depository services, as well as loans for commercial, industrial, residential mortgage, and consumer purposes. The company operates through two reportable operating segments: Wholesale Banking and Consumer Banking, with corporate support functions such as corporate treasury and others included in Corporate Other. It derives maximum revenue from the Wholesale Banking segment.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.